Ongoing Projects:

1. A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Immunogenicity and Safety of Single dose of Dengue Tetravalent Vaccine, Live Attenuated (Recombinant, Lyophilized) – “DengiAll” of Panacea Biotec Limited in Healthy Indian Adults – Preparatory budget – Principal Investigator
2. “Prevalence of Select Sexually Transmitted infections and Reproductive Tract infections among selected High Risk Groups: MSM, FSW, IDU in India” (NACO, GoI) – Principal Investigator

As  Mentor

1. Sentinel survey of the high-risk population through community based organizations for the detection of Human MPOX virus infection in India – Mentor
2. HIV Sentinel Surveillance (Western and Central India): Program-research (NACO, GoI) – Principal Investigator

Completed Research Support: (last 10 years only)
    1. ‘WHO-ICMR SOLIDARITY TRIAL PLUS –-India titled “An international randomized trial of
     additional treatments for COVID-19 in hospitalized patients who are receiving the local standard
     of care” (ICMR ) – Principal Investigator
    2. ICMR/SII-COVOVAX: A phase 3, observer-blind, randomized, controlled study to determine the
    safety and immunogenicity of Covovax [Sars-CoV-2 recombinant spike protein nanoparticle
    vaccine (Sars-CoV-2 rS) with Matrix-M1™ adjuvant] in Indian adults., PI /Co-PI (ICMR )
    3. The ART Impact Evaluation- India Study (ARTIE-India): Evaluation of Impact of Antiretroviral
    Therapy under the National AIDS Control Programme in India’ (2017-2020)
    4. An assessment of feasibility of operationalization of ‘Early or Immediate ART’ to HIV infected
    partners as a combination intervention among HIV sero-discordant couples in India.(2016 -2019)
    5. In-country data validation for Elimination of mother-to-child transmission of HIV and Syphilis in
    Six Indian states, 2017. Phase I: Maharashtra (2017)
    6. HPTN 052:A Randomized Trial to Evaluate the Effectiveness of Antiretroviral Therapy plus HIV
    Primary Care versus HIV Primary Care alone to prevent the Sexual Transmission of HIV-1 in
    Sero-discordant Couples. (2011-2016)
    7. Utility of Prevention-of-Mother-to-Child HIV Transmission Program Data for HIV Surveillance
    (2015 and 2017)
    8. Relation Between Genetic Markers of Drug Resistance and Susceptibility Profile of N.
    gonorrhea strains’- A study in 4 centres in India (2014-2015)
    9. ACTG 5282:A Randomized, Phase II Trial to Compare an HPV Test-and-Treat Strategy to a
    Cytology-based Strategy for Prevention of CIN 2+ in HIV-infected Women (2013-2015)

Education Qualifications :
1) MD (Dermatology, Venereology, and Leprology), 1992, Byramjee Jeejeebhoy (B.J.) Medical
College, University Of Pune.
2) MBBS (Medicine and Surgery), 1988, Byramjee Jeejeebhoy (B.J.) Medical College, University of
Pune (Internship completed in 1989)
3) PG Diploma in Epidemiology, 2014, Public Health Foundation of India

Dr. Sheela Godbole MD is the Director of ICMR-National AIDS Research Institute (ICMR-NARI), Pune and
holds additional charge as Director of the ICMR-National Institute of Virology, Pune as well. An alumnus
of Byramjee Jeejeebhoy Medical College (BJMC), Pune, she obtained her MD in 1992.

A clinician by training, she spent nearly a decade caring for persons with HIV and STI’s which led her to a
full time career in research and she joined the Indian Council of Medical Research in 2001. She has been
the Principal Investigator of many large studies and trials in India and site PI for multinational trials with
the HIV Prevention and the AIDS Clinical Trials Networks. She was the National Coordinator for the
WHO-Solidarity Trial. She serves on various national committees & technical resource groups for
Government of India and is a WHO Technical Advisory Group member. In addition to her administrative
responsibilities & leading over a 100 scientists in two institutions, she continuous her research work in
HPV, HIV and Dengue. Her work has been published in leading journals like New England Journal of
Medicine, Lancet, Lancet-ID, Journal of AIDS and Indian Journal of Medical Research.

An experienced clinician researcher, a committed leader, communicator and mentor. She plans to guide
the institute towards newer horizons in clinical trials and other clinical virologic research.

Research Areas: Clinical Trials for treatment and prevention of HIV, COVID, HPV and other viral disease,
clinical-epidemiological research (HIV, STI surveillance, HIV-cancer), Program implementation research,
prevention and care, elimination of vertical transmission of HIV and Syphilis.

Personal Statement

An experienced clinician-researcher, a leader, passionate communicator with strong technical, grant-
writing, project management-implementation and administrative skills, I work well under pressure.
As a consultant caring for persons with HIV and STI in the pre-antiretroviral treatment era in India, I was
drawn to fill gaps in HIV, and STI care through research. For over two decades, I have led clinical Trials
for HIV prevention and treatment (antiretrovirals) and most recently COVID-19 and am about to initiate
national phase 3 trial for Dengue vaccine in India. I have also focused on clinical-epidemiological
research in HIV, STI’s, HPV, HIV& cancer. Additionally have been involved collaboratively in basic
science research in HIV immunology, HIV drug resistance and genetic basis of antimicrobial resistance of
N.gonorrhoeae in India. I led a research clinic providing care for sexually transmitted infections and HIV
for over 15 years.
I have contributed to India’s commitment to eliminate Mother to Child Transmission of HIV and Syphilis
in 2020 as a key member of the National Core Group formulated by the Ministry and by conducting a
unique Data Validation study that identified key gaps and action points for NACO and RMNCHA+
programs. I recently completed the first evaluation of the impact of the ‘Free antiretroviral treatment
(ART) program’ of the Government of India, which is the largest financial outlay under the NACP and
set up a strong nationwide collaboration for the same.
I have successfully written, received and implemented many national and internationally funded
extramural research grants and currently manage large project budgets and lead collaborations with
multiple partner institutes in India (ICMR and non-ICMR). As Investigator of Record and later grantee PI
for the Phase III Randomised Controlled Clinical Trial for HIV prevention (HPTN 052) since 2008, I
played a major role in setting up systems to ensure good implementation of clinical trials at ICMR-NARI.
The years of experience as a Clinical Research Site Leader and later on as the Principal Investigator of the
NIH USA-funded NARI Clinical Trial Unit (CTU) honed my scientific temperament and people
management skills.

I have successfully been able to liaise and interact with State AIDS Control Societies, state health
systems, and medical colleges especially microbiology, community medicine and medicine departments
across India, and other institutions as well for research studies.

I currently serve on the WHO Technical Advisory Group for STI research priority setting and have served
on various international scientific committees. Through participation in ‘expert consultations’, technical
resource groups and guideline development committees, I provide technical support to Government of
India’s National AIDS Control Programme (NACP). I am responsible for HIV Sentinel Surveillance in 5
states and 2 Union Territories of Western India and have helped test out newer methods of surveillance
that were adapted nationally. In response to the COVID-19 pandemic, I am currently leading the ICMR-
India-WHO Solidarity trials for treatment options for Hospitalised COVID Patients as the National
Principal Investigator and coordinator and played a lead role for bridging vaccine trials. I led the initiation
of the India- adult bridging trial for ‘Covovax’ COVID vaccine on behalf of ICMR in 2020-21 and this
has now received Emergency Use Authorization from the Drugs Controller General of India. Currently I
am Director of ICMR-National AIDS Research Insitute in Pune and steering the institute into research
beyond HIV and STI’s. I am also Director in Charge of National Insitute of Virology (ICMR-NIV).

Awards and Honors:

1. ICMR-Intramural Research & Innovation Meet 2023- ‘ Best Research Publication Award’
2. Phoenix Leading Lady Award for Excellence in Research in Maharashtra, March 2017
3. Selected as an ICMR fellow for the “Collaborative Indo-Swedish Public Health Initiative for Research Excellence” (INSPIRE) Indo-Swedish Program in 2011-12
4. “Young Achievers Award for Women”: for contributions in the field of Health and Medicine in Pune City over the last decade. 4th January 2003 in Pune, All India Women’s Conference
5. “Best Participant award”: WHO Disease Burden Workshop 2001.
6. “A. C. Parikh award for Best Case Paper presentation”, presented by Indian Association of Dermatologists and Venereologists Maharashtra Branch 1992.
7. Scientific Breakthrough of 2011”: The paper “Prevention of HIV-1 Infection with Early Antiretroviral Therapy” published in New England Journal of Medicine July 18 2011, was identified as Scientific Breakthrough of 2011 in December 2011 by the prestigious journal ‘Science’. I am a Co-Author on the mast head of this paper. This paper has become a citation classic with nearly 5000 citations

Membership of Professional / Advisory Bodies / Committees:

1. Governing Council of Indian Council of Medical Research -ICMR, N Delhi – (Member)
2. Executive Council of Indian Council of Medical Research -ICMR, N Delhi – (Member)
3. Member Governing Council of Institute of Advanced Virology, Kerala (ex-officio-as DIC NIV) Nov 2022 onwards
4. Life Member of Indian Virological Society January 2024 onwards
5. Invited Member NTAGI, GOI (ex-officio-as DIC NIV) Nov 2022 onwards
6. WHO Technical Advisory Group (TAG) on Sexually Transmitted Infection (STI) research priority setting- 2021
7. WHO and UK Government ‘Round Table on the international clinical trials infrastructure’- 2021
8. WHO ad hoc consultation COVID-19 therapeutics Knowledge gaps and research priorities
9. India Task Force Lancet COVID-19 Commission

National Level technical and advisory committees constituted by National AIDS Control
Organization (MoH&FW) GOI for the National AIDS Control Program (NACP)
1. Technical Working Sub-Group for Strategic Plan and Framework for EVTHS- Lead 2022
onwards
2. Technical Resource Group for NACO Lab services- Chair, 2022 onwards
3. Technical Resource Group for Female Sex Workers (FSW), Member 2021 onwards
4. Technical Resource Group on Surveillance and Epidemiology Member- 2021 onwards
5. Co-Chair, National Sub-Group for STI Surveillance, 2021 onwards
6. National Sub-Group for HIV Burden Estimations - 2021 onwards
7. National Working Group- District Level HIV Estimations 2019-20,
8. Technical Resource Group for HIV Estimations 2017-18- Member
9. Technical Resource Group for HIV Sentinel Surveillance 2017, - Member
10. National Consultation-Elimination of Mother to Child Transmission of HIV -Private Sector
participation, -Member
11. National Core Group on Elimination of Mother to Child Transmission of HIV and Syphilis
12. Subcommittee for development of Verification and Validation protocols for Elimination of Mother
to Child Transmission of HIV and Syphilis (EMTCT) NACO MoH&FW, GOI: Member
13. Technical Resource Group for Prevention of Parent to Child Transmission of HIV, NACO,
MoH&FW, GOI- Member
14. National Strategic Plan (2017-24) development (NACO road map): for prevention and
elimination of HIV/AIDS in India- Technical Sub-Committee Monitoring, Evaluation and
Surveillance: Member
15. National Strategic Plan (2017-24) development: NACO road map for prevention and elimination
of HIV/AIDS in India constituted by NACO MoH&FW, GOI: Technical Sub-Committee for a.
EMTCT of HIV & b. HIV-TB: Member
16. National HIV Testing Guidelines Writing Group: Technical Expert and Sub Committee member
Dec 2015 – July 2016. (The guidelines were published in Dec 2016)
17. Regional STI Centre National Mentoring Committee: Committee was constituted in September
2012- Member
18. NACO Technical Resource Group’s for NACP IV planning: Member of following sub-groups-
i. Sexually Transmitted Infections Working group and STI Surveillance

ii. Research and Evaluation: Strategic Information Management Unit

19. NACO Technical Resource Group’s for NACP IV planning: Member of following sub-groups-
i. Sexually Transmitted Infections Working group and STI Surveillance
ii. Research and Evaluation: Strategic Information Management Unit

Consultations by WHO/ UNAIDS/GOI
1. Expert consultation -Newer Methods of Surveillance and HIV estimations in India, 2018
2. Expert Consultation for HIV Surveillance and Estimations 2016: Member and Resource Person.
3. Expert Consultation for HIV Testing: WHO and NACO Nov 2015 Member
4. Expert Consultation for the Development of a Strategy towards Elimination of Congenital Syphilis
(ECS) 2013 : Member

Scientific Advisory Committee

1. ICMR-National Institute of Virology – Member
2. ICMR-National Institute of Immunohaematology - Member

Ethics Committees
1. Ethics Committee: National Institute of Virology –Member
2. Ethics Committee: UDIRT, Maharashtra University of Health Sciences (MUHS), Nashik,
Maharashtra. February 2006-8

Other International:
1. India Task Force- Lancet COVID Commission (Member)
2. Prevention Science Working Group- HIV Prevention Trial Network, DAIDS NIH USA
(completed)
3. Women’s Health Committee, AIDS Clinical Trials Network, DAIDS NIH USA (completed)
4. Women at Risk (WaTR) Scientific Committee of HIV Prevention Trial Network, DAIDS NIH
USA (completed)
5. Performance Evaluation Committee, AIDS Clinical Trials Network, DAIDS NIH USA
(completed)

Professional Bodies:
1. Indian Association of Preventive & Social Medicine (IAPSM)- Life member
2. Indian Association of Dermatologists, Venereologists and Leprologists (IADVL) - Life member
3. Indian Medical Association- Life Member

*Actively involved in clinical care of persons at risk of or with HIV as a clinician until recently

Major Academic and Research Achievements:

Research Experience:

Dr. Godbole has led many nationally and internationally funded research projects/clinical trials as Principal Investigator over two decades

Research in a Lead Role: (N=24 Projects)  

As Principal Investigator (PI) / Investigator of record (IoR) /Nodal Officer

1. “Facilitators and Barriers for Uptake of COVID-19 Vaccine Precaution Dose among adult Population: Qualitative analysis across six different states of India” Sheela Godbole, Vishal Diwan, Saibal Das, Mahendra M Reddy, Madhanraj Kalyanasundaram, Dilipkumar Rajendran, Dipankar Biswas, Megha S Mamulwar, RR Tiwari, Joydeep Majumder. Frontiers in Public Health 11, 1293600,2024

2. “Projected impact of fast-tracking of anti-retroviral treatment coverage on vertical transmission of HIV in India” Pradeep Kumar, Chinmoyee Das, Subrata Biswas, Nidhi Priyam, Lalit Singh Kharayat, Damodar Sahu, Sanjay K. Rai, Sheela V. Godbole, Elangovan Arumugam, P. V. M. Lakshmi, Shanta Dutta, H. Sanayaima Devi , Arvind Pandey, Dandu Chandra Sekhar Reddy, Sanjay Mehendale, Shobini Rajan. PLOS Glob Public Health 4(9), e0003702, 2024

3. “WHO global research priorities for sexually transmitted infections” Sami L Gottlieb, Erica Spielman, Laith Abu-Raddad, Adeniyi Kolade Aderoba, Laura H Bachmann, Karel Blondeel, Xiang-Sheng Chen, Tania Crucitti, Gabriela Garcia Camacho, Sheela Godbole, Rodolfo Gómez Ponce de Leon, Somesh Gupta, Joumana Hermez, Naoko Ishikawa, Jeffrey D Klausner, Firdavs Kurbonov, Ismael Maatouk, Ahmed Mandil, Maeve B Mello, Angelica Espinosa Miranda, Fausta Shakiwa Mosha, Joseph Chukwudi Okeibunor, Jason J Ong, Remco P H Peters, Freddy Pérez, Nicole Seguy, Kate L Seib, Mukta Sharma, Tim Sladden, Barbara Van Der Pol, Peter J White, Teodora Wi, Nathalie Broutet. Lancet Glob Health 12(9), e1544-e1551, 2024

4. ‘Monocyte to lymphocyte ratio and hemoglobin level to predict tuberculosis after antiretroviral therapy initiation’ Sivaporn Gatechompol, Stephen J Kerr, Sandra W Cardoso, Wadzanai Samaneka, Srikanth Tripathy, Sheela Godbole, Manisha Ghate, Cecilia Kanyama, Mulinda Nyirenda, Patcharaphan Sugandhavesa, Andre Machado, Frank Van Leth, Thomas B Campbell, Susan Swindlells, Anchalee Avihingsanon, Frank Cobelens AIDS 38 (1), 31-38

5. ‘Augmenting progress on the elimination of vertical transmissions of HIV in India: Insights from Spectrum-based HIV burden estimations’ Pradeep Kumar, Chinmoyee Das, Udayabhanu Das, Arvind Kumar, Nidhi Priyam, Varsha Ranjan, Damodar Sahu, Sanjay K Rai, Sheela V Godbole, Elangovan Arumugam, Lakshmi Pvm, Shanta Dutta, H Sanayaima Devi, Arvind Pandey, Dandu Chandra Sekhar Reddy, Sanjay Mehendale, Shobini Rajan PLOS Global Public Health 3 (8), e0002270

6. ‘Age-Specific Prevalence of Anal and Cervical Human Papillomavirus Infection and High-Grade Lesions in 11 177 Women by Human Immunodeficiency Virus Status: A Collaborative Pooled Analysis of 26 Studies’ Feixue Wei, Ningshao Xia, Rebeca Ocampo, Marc T Goodman, Nancy A Hessol, Beatriz Grinsztejn, Ana P Ortiz, Fanghui Zhao, Erna M Kojic, Rupert Kaul, Isabelle Heard, Imran O Morhason-Bello, Anna-Barbara Moscicki, Alexandra de Pokomandy, Joel M Palefsky, Luana L S Rodrigues, Racheal S Dube Mandishora, Reshmie A Ramautarsing, Silvia Franceschi, Sheela V Godbole, Fernanda K Tso, Lynette J Menezes, Chunqing Lin, Gary M Clifford. J Infect Dis 227(4),488-497, (2023) doi: 10.1093/infdis/jiac108.
7. ‘Prevalence of Long COVID Symptoms: An Observational, Cross-Sectional Follow-Up Study in Haryana, India’ . Dhruva Chaudhry, Shweta Khandelwal, Chandrika Bahadur, Benjamin Daniels, Malay Bhattacharyya, Raman Gangakhedkar, Sapna Desai, Jishnu Das, Usha Gupta, Veena Singh, Shalu Garg, Liza Bharadwaj, Vinod Chayal, Varun Arora, Pawan Kumar Singh, Nizamuddin Khan, Sheela Godbole The Lancet Regional Health-Southeast Asia

8. ‘A protocol for feasibility of plasma based GeneXpert platform and Dried Blood Spot (DBS) based Abbott platform for HIV-1 viral load testing among the people living with HIV attending ART centers in India’ Suchit Kamble, Pallavi Shidhaye, Anupam Mukherjee, Madhuri Tak, Shilpa Bembalkar, Sumit Aggarwal, Arpita Deb, Neha Kapoor, Vinita Verma, Chinmoyee Das, Smita Kulkarni, Manisha Ghate, Sheela Godbole PLoS ONE 18(5): e0285942. https://doi.org/10.1371/journal.pone.0285942

9. ‘ Safety and immunogenicity of SII-NVX-CoV2373 (COVID-19 vaccine) in adults in a phase 2/3, observer-blind, randomised, controlled study’ Prasad S Kulkarni, Abhijit Kadam, Sheela Godbole, Varsha Bhatt, Abhishek Raut, Sunil Kohli, Santanu Tripathi, Praveen Kulkarni, Rakhi Ludam, Madhav Prabhu, Ashish Bavdekar, Nithya J Gogtay,et al The Lancet Regional Health-Southeast Asia 10:100139, (2023) doi: 10.1016/j.lansea.2022.100139.

10. ‘HIV-1 exploits Hes-1 expression during pre-existing HPV-16 infection for cancer progression’ Serena D’Souza, Arati Mane, Linata Patil, Aazam Shaikh, Madhuri Thakar, Vandana Saxena, Leila Fotooh Abadi, Sheela Godbole, Smita Kulkarni, Raman Gangakhedkar, Padma Shastry, Samiran Panda Virus Disease 34 (1) 29-38 (2023)
11. ‘Pregnancy rates and clinical outcomes among women living with HIV enrolled in HPTN 052, AIDS Care’ Sahar Z. Zangeneh, Ethan A. Wilson, Surabhi Ahluwalia, Deborah J. Donnell, Ying Q. Chen, Beatriz Grinsztejn, Marineide G. Melo, Sheela V. Godbole, Mina C. Hosseinipour, Taha Taha, Johnston Kumwenda, Marybeth McCauley, Myron S. Cohen & Karin Nielsen-Saines 35(6), 824-832 (2023) doi: 10.1080/09540121.2022.2141187
12. “Diversity in HIV epidemic transitions in India: An application of HIV epidemiological metrices and benchmarks”Pradeep KumarID1 , Chinmoyee Das , Arvind Kumar , Damodar Sahu, Sanjay K. Rai, Sheela Godbole , Elangovan Arumugam , Lakshmi P. V. M. , Shanta Dutta , H. Sanayaima Devi , Vishnu Vardhana Rao Mendu , Shashi Kant , Arvind Pandey, Dandu Chandra Sekhar Reddy,  Sanjay Mehendale, Shobini Rajan

PLoS ONE 17(7): e0270886. https://doi.org/10.1371/ journal.pone.0270886

13. “Remdesivir and three other drugs for hospitalised patients with COVID-19: final results of the WHO Solidarity randomised trial and updated meta-analyses”. - WHO Solidarity Trial ConsortiumThe Lancet, thelancet.com Published online May 2, 2022 https://doi.org/10.1016/S0140-6736(22)00519-0
14. “Age-specific prevalence of anal and cervical HPV infection and high-grade lesions in 11 177 women by HIV status: a collaborative pooled analysis of 26 studies”.  Feixue Wei, Ningshao Xia, Rebeca Ocampo, Marc T Goodman, Nancy A Hessol, Beatriz Grinsztejn, Ana P Ortiz, Fanghui Zhao, Erna M Kojic, Rupert Kaul,Isabelle Heard, Imran O Morhason Bello, Anna-Barbara Moscicki, Alexandra de Pokomandy, Joel M Palefsky, Luana L S Rodrigues, Racheal S Dube Mandishora, Reshmie A Ramautarsing, Silvia Franceschi, Sheela V Godbole, Fernanda K Tso, Lynette J Menezes, Chunqing Lin, Gary M Clifford  The Journal of Infectious Diseases, 23 March 2022. jiac108, https://doi.org/10.1093/infdis/jiac108

15. “A randomized clinical trial of HPV test-and-treat as compared to cytology-based screening for prevention of cervical cancer among women living with HIV: AIDS Clinical Trials Group Protocol A5282”. Wilkin T, Chen H, Sahasrabuddhe V, Matining R, Mngqibisa R, Chinula L, Mbilizi Y, Magure T, Omoz-Oarhe AE, Rassool M, Riviere C, Bhosale R, Godbole S, Naranjo R, Coombs R, Michelow P, Godfrey C, Firnhaber C.Clin Infect Dis. 2022 Mar 16:ciac213. doi: 10.1093/cid/ciac213. Online ahead of print. PMID: 35294524

16. “Quantifying inadvertent data-duplication- findings from validation of antenatal-registration and HIV testing data-sets from an Indian state” Sheela Godbole , Shweta Chidrawar , Suvarna Sane, Yashika Bansal , Asha Hegde , Shilpa Bembalkar , Suchit Kamble , Megha Mamulwar , Shrikala Acharya , Vijay Bawiskar , Laxmi Ramakrishnan , Yujwal Raj , Raman Gangakhedkar, Ashok Kumar, D C S Reddy, Arvind Pandey, Tobi Saidel, Naina Rani, Nicole Seguy, K S Sachdeva .   International Journal of Epidemiology, September 2021, Vol 50, Issue Supplement _1

17. “Sexually transmitted infections among HIV serodiscordant partners: A secondary analysis of HIV Prevention Trial Network 052” Maganizo B Chagomerana, Mina C Hosseinipour, Jose Henrique Pilotto, Sharlaa Badal-Faesen, Mulinda Nyirenda, Emily Shava, Sheela V Godbole, Victor Akelo, Suwat Chariyalertsak, Ravindre Panchia and Myron Cohen. International Journal of STD & AIDS 2021 Jul DOI: 10.1177/09564624211030368.
18. “District-level HIV estimates using the spectrum model in five states of India, 2017” Kumar P, Sahu D, Rajan S, Mendu VV, Das C, Kumar A, Chandra N, Camara B, Rai S, Arumugam E, Godbole SV, Singh SK, Kant S, Pandey A, Reddy DC, Mehendale S.Medicine 2021;100:28(e26578).
19. “Repurposed antiviral drugs for COVID-19–interim WHO SOLIDARITY trial results” The members of the writing and steering committees (H. Pan, R. Peto, A.-M. Henao-Restrepo, M.-P. Preziosi, V. Sathiyamoorthy, Q. Abdool Karim, M.M. Alejandria, C. Hernández García, M.-P. Kieny, R. Malekzadeh, S. Murthy, K.S. Reddy, M. Roses Periago, P. Abi Hanna, F. Ader, A.M. Al-Bader, A. Alhasawi, E. Allum, A. Alotaibi, C.A. Alvarez-Moreno, S. Appadoo, A. Asiri, P. Aukrust, A. Barratt-Due, S. Bellani, M. Branca, H.B.C. Cappel-Porter, N. Cerrato, T.S. Chow, N. Como, J. Eustace, P.J. García, S. Godbole, E. Gotuzzo, L. Griskevicius, R. Hamra, M. Hassan, M. Hassany, D. Hutton, I. Irmansyah, L. Jancoriene, J. Kirwan, S. Kumar, P. Lennon, G. Lopardo, P. Lydon, N. Magrini, T. Maguire, S. Manevska, O. Manuel, S. McGinty, M.T. Medina, M.L. Mesa Rubio, M.C. Miranda-Montoya, J. Nel, E.P. Nunes, M. Perola, A. Portolés, M.R. Rasmin, A. Raza, H. Rees, P.P.S. Reges, C.A. Rogers, K. Salami, M.I. Salvadori, N. Sinani, J.A.C. Sterne, M. Stevanovikj, E. Tacconelli, K.A.O. Tikkinen, S. Trelle, H. Zaid, J.-A. Røttingen, and S. Swaminathan)   New England Journal of Medicine(NEJM) online- 2^nd December 2020  Print – February 2021

20. “Findings from the 2017 HIV estimation round & trend analysis of key indicators 2010-2017: Evidence for prioritising HIV/AIDS programme in India” Damodar Sahu , Pradeep Kumar , Nalini Chandra, Shobini Rajan, D.K. Shukla, S. Venkatesh, Saritha Nair, Anil Kumar, Jitenkumar Singh, Srikanth Reddy, Sheela Godbole, Elangovan, M.K. Saha, Sanjay Rai, P.V.M. Lakshmi, T. Gambhir, Savina Ammassari, Deepika Joshi, Amitabh Das, Poonam Bakshi , Sabyasachi Chakraborty, Amol Palkar, S.K. Singh, D.C.S. Reddy, Shashi Kant, Arvind Pandey & M. Vishnu Vardhana Rao. Indian J Med Res 151, June 2020, pp 562-570 DOI: 10.4103/ijmr.IJMR_1619_19

21. “Persons living with HIV continue to present late for care: A trend analysis from 2011 to 2015”. Kadam AV, Bembalkar SC, Panchal NU,Mamulwar MS, Shete AV, Godbole SV.*.  Indian J Sex Transm Dis 2019; 40:133-8.

22. "Evaluation of key survey components of bio-behavioral surveillance among HIV high-risk subpopulation in Western India" Brahme RG, Godbole SV, Gangakhedkar RR, Sachdeva KS, Verma V, Risbud AR. Indian J Public Health 2019;63:305-12.

23. “Optimization of extraction of genomic DNA from archived dried blood spot (DBS): potential application in epidemiological research & bio banking”. Kumar A, Mhatre S, Godbole S et al. Gates Open Research 2019, 2:57   [version 3; peer review: 2 approved, 1 approved with reservations]  (https://doi.org/10.12688/gatesopenres.12855.3)

24. “Declining Trends in HIV Prevalence Among Women Attending Antenatal Care Clinics Obfuscate the Continued Vulnerability of Adolescent Girls in Maharashtra, India (2005–2017)”
    Brahme, Radhika; Godbole, Sheela*; Sonawale, Suvarna; Kadu, Chitra; Yadav, Rajesh; Dulhani, Nisha; Lokhande, Amit; Kumar, Pradeep; Deoraj, Pramod; Acharya, Shreekala; Rajan, Shobini; Venkatesh, Srinivas JAIDSJournal of Acquired Immune Deficiency Syndromes, September 1, 2019,82(1):e13-e17 Letters to the Editor

25. “Cervical determinants of anal HPV infection and high-grade anal lesions in women: a collaborative pooled analysis”. Chunqing Lin, Jiri Slama, Paula Gonzalez, Marc T Goodman, Ningshao Xia, Aimée R Kreimer, Ting Wu, Nancy A Hessol, Yurii Shvetsov, Ana P Ortiz, Beatriz Grinsztejn, Anna-Barbara Moscicki, Isabelle Heard, María del Refugio González Losa, Erna M Kojic, Maarten F Schim van der Loeff, Feixue Wei, Adhemar Longatto-Filho, Zizipho A Mbulawa, Joel M Palefsky, Annette H Sohn, Brenda Y Hernandez, Katina Robison, Steve Simpson Jr, Lois J Conley, Alexandra de Pokomandy, Marianne A B van der Sande, Racheal S Dube Mandishora, Lays P B Volpini, Alessandra Pierangeli, Byron Romero, Timothy Wilkin, Silvia Franceschi, Carmen Hidalgo-Tenorio, Reshmie A Ramautarsing, Ina U Park, Fernanda K Tso, Sheela Godbole, Kathleen W M D’Hauwers, Borek Sehnal, Lynette J Menezes, Sandra A Heráclio, Gary M Clifford. Lancet Infectious Diseases Published online June 13, 2019 http://dx.doi.org/10.1016/S1473-3099(19)30164-1   
26. “Understanding racial diversities in Kaposi's sarcoma”. Sheela Godbole, Manisha Ghate, Sanjay Mehendale. Indian Journal of Medical Research 149, March 2019, pp 319-321 DOI:10.4103/ijmr.IJMR_2164_18IJMR_2164_18 
27. “Functional invariant Natural Killer T cells secreting cytokines are associated with non-progressive HIV-1 infection but not with suppressive ART” Singh D, Ghate M, Godbole S, Kulkarni S and Thakar M.  Frontiersin Immunology, (section T Cell Biology). 9:1152. Doi:10,3389/fimmu.2018.01152. 24 May 2018

28. “Use of computer-assisted personal interviewing and information management system in a survey among HIV high-risk groups in India: Strengths, weaknesses, opportunities, and threats analysis” Brahme R, Godbole S, Gangakhedkar R, Sachdeva KS, Verma V, Risbud A. Indian J Community Med 2018;43:107-12

29. “Productively infected CD4+ cells express higher Human telomerase reverse transcriptase levels indicating a possible mechanism of persistence in HIV infection” Poonam Suryawanshi, Sheela Godbole, Jyoti Pawar. Madhuri Thakar , Ashwini Shete Journal of Microbiology and Immunology. First published: 25 March 2018 https://doi.org/10.1111/1348-0421.12585
30. “Differing HIV vulnerability among female sex workers in a high HIV burden Indian state” Mamulwar M, Godbole S*, Bembalkar S, Kamble P, Dulhani N, Yadav R, et al. (2018). PLoS ONE 13(2): e0192130. https://doi.org/10.1371/journal.pone.0192130
31. “HIV Drug Resistance in Adults Receiving Early Versus Delayed Antiretroviral Therapy: HPTN 052”   Palumbo PJ, Fogel JM, Hudelson SE, Wilson EA, Hart S, Hovind L, Piwowar-Manning E, Wallis C^,  Papathanasopoulos MA, Morgado MG, Saravanan S, Tripathy S , Eron JJ, Gallant JE, McCauley M, Gamble T, Hosseinipour MC, Kumarasamy N, Hakim JG, Pilotto JH, Kumwenda J, Akelo V, Godbole SV, Santos BR, Grinsztejn B, Panchia R, Chariyalertsak S, Makhema J, Badal-Faesen S, Chen YQ, Cohen MS, Eshleman SH.  Journal of Acquired Immune Deficiency Syndromes (JAIDS) December 2017.DOI 10.1097/QAI.0000000000001623
32. “Antibiotic susceptibility pattern of Neisseria gonorrhoeae strains isolated from five cities in India during 2013–2016” Sangeeta V. Kulkarni, Manju Bala Syeeda A. Muqeeth [...] Sheela V Godbole*  Journal of Medical Microbiology Dec 2017
33. “Cross-reactive influenza-specific antibody-dependent cellular cytotoxicity-mediating antibodies in HIV-infected Indian individuals”. Nehul S, Kulkarni A, Pawar S, Godbole S, Ghate M, Thakar M. Infect Dis (Lond). 2017 Aug 4:1-9. doi: 10.1080/23744235.2017.1361547.
34. “Association of HIV diversity and virologic outcomes in early antiretroviral treatment” HPTN 052.” Palumbo PJ,Wilson EA, Piwowar-Manning E, McCauley M, Gamble T, Kumwenda N, Makhema J, Kumarasamy N, Chariyalertsak S, Hakim JG, Hosseinipour MC, Gonçalves de Melo M, Godbole SV, Pilotto JH, Grinsztejn B, Panchia R, Chen YQ, Cohen MS, Eshleman Sh, Fogel JM. PLoS One. May 2017.
35. “Virologic outcomes in early antiretroviral treatment: HPTN 052”. Eshleman SH, Wilson EA, Zhang XC, Ou SS, Piwowar-Manning E, Eron JJ, McCauley M, Gamble T, Gallant JE, Hosseinipour MC, Kumarasamy N, Hakim JG, Kalonga B, Pilotto JH, Grinsztejn B, Godbole SV, Chotirosniramit N, Santos BR, Shava E, Mills LA, Panchia R, Mwelase N, Mayer KH, Chen YQ, Cohen MS, Fogel JM HIV Clinical Trials e-pub April 7 2017.
36. “Low immune activation is associated with higher frequencies of central memory T cell subset in a cohort of Indian long term non-progressors”. Saxena V, Bichare S, Singh D, Ghate M, Godbole S, Kulkarni S, Gangakhedkar R, Paranjape R, Thakar M. AIDS Res Hum Retroviruses 2017 Feb;33 (2):121-125. doi:10.1089/AID.2016.0210.

37. “CD1d restricted Natural killer T cells are preserved in Indian long term non progressors (LTNPs)” Singh D, Ghate M, Godbole S, Kulkarni S, Thakar M Feb  2017 JAIDS J Acquir Immune Defic Syndr. doi:10.1097/QAI.0000000000001322

38. “Indian Long-term Non-Progressors Show Broad ADCC Responses with Preferential Recognition of V3 Region of Envelope and a Region from Tat Protein”.Kulkarni A, Kurle S, Shete A, Ghate M, Godbole S, Madhavi V, Kent SJ, Paranjape R, Thakar M. Frontiers in Immunology 8(14)January 2017. DOI: 10.3389/fimmu.2017.00005

39. “Development of IFN- secretory ELISPOT based assay for screening of ADCC responses.” Shete A, Suryawanshi P, Chavan C, Kulkarni A, Godbole S, Ghate M and Thakar M. Journal of Immunological methods 2016 Dec 5.

40. “Fitting HIV Prevalence 1981 Onwards for Three Indian States Using the Goals Model and the Estimation and Projection Package.” Bhatnagar T, Dutta T, Stover J, Godbole S, Sahu D, Boopathi K, Bembalkar S, Singh KJ, Goyal R, Pandey A, Mehendale SM.                         PLoS One. 2016 Oct 6;11(10):e0164001.

41. "HIV and Cancer Registry Linkage identifies a Substantial Burden of Cancers in Persons with HIV in India". Sheela V Godbole et al Medicine 95: 37, September 2016

42. “Antiretroviral Treatment for Prevention of HIV Transmission: The Final Results of the HIV Prevention Trials Network (HPTN) 052 Trial”.  M S. Cohen,  Q. Chen, M McCauley, T. Gamble, M.C.Hosseinipour, N. Kumarasamy, J.G. Hakim, J.Kumwenda, B Grinsztejn, J.H.S. Pilotto, S.V. Godbole., S.Chariyalertsak, B.R. Santos, K H. Mayer, I F. Hoffman, S.H. Eshleman, E Piwowar-Manning, L. Cottle, X.C. Zhang, J. Makhema, L.A. Mills, J. Eron, J. Gallant, D.Havlir, S. Swindells, V.Elharrar, D Burns, T.E.Taha, K.Nielsen-Saines, D Celentano, M. Essex, S.E. Hudelson, A.D.Redd.and T. R. Fleming, for the HPTN 052 Study Team*  New England Journal of Medicine  18 July 2016 online first   DOI: 10.1056/NEJMoa1600693

43. "HIV infected CD4+ T cells use T-bet dependent pathway for production of IL-10 upon antigen recognition". Scandinavian Journal of Immunology 83(4):288-296 May 2016 DOI: 10.1111/sji.12422. Shete A, Suryawanshi P, Godbole S, Pawar J, Paranjape R, Thakar M

44. “HIV drug resistance in adults failing early antiretroviral treatment”. JAIDS Journal of Acquired Immune Deficiency SyndromesFebruary 2016 DOI: 10.1097    Fogel, Jessica M.; Hudelson, Sarah E.; Ou, San-San; Hart, Stephen; Wallis, Carole; Morgado, Mariza G.; Saravanan, Shanmugam; Tripathy, Srikanth; Hovind, Laura; Piwowar-Manning, Estelle Sabin, Devin; McCauley, Marybeth; Gamble, Theresa; Zhang, Xinyi Cindy; Eron, Joseph J.; Gallant, Joel E.; Kumwenda, Johnstone; Makhema, Joseph; Kumarasamy, Nagalingeswaran; Chariyalertsak, Suwat; Dr.; Hakim, James; Badal-Faesen, Sharlaa; Akelo, Victor; Hosseinipour, Mina C.; Santos, Breno Riegel; Godbole, Sheela V; Pilotto, Jose Henrique; Grinsztejn, Beatriz; Panchia, Ravindre ; Mayer, Kenneth H.; Chen, Ying Q.; Cohen, Myron S.; Eshleman, Susan H

45. “Fallacy of Using Odds Ratio as A Measure Of Association In Prospective Studies.” Asian J Sc Tech. 2015; 6(11):1990-92 30 Nov 2015. Rajneesh K Joshi, Monil Anurag Khera and Sheela V. Godbole

46. “Predictors of Bisexual Behaviour among MSM Attending Intervention Sites May Help in Prevention Interventions for This Bridge to the Heterosexual Epidemic in India: Data from HIV Sentinel Surveillance” Godbole S,Sane S, Kamble P, Raj Y, Dulhani N, et al. (2014  PLoS ONE 9(9):  doi: 10.1371/journal.pone.0107439

47. “Prevalence of anal Human papillomavirus (HPV) infection among HIV-infected women from India.” Sheela V. Godbole, Arati K. Mane, Shweta R. Chidrawar, Usha R. Katti, Shubhangi Kalgutkar, Prachi V.Athavale, Jyoti S. Pawar, Manisha M. Ratnaparkhi, Mallika Alexander, Arun R. Risbud, Ramesh S.Paranjape,   JAIDS Journal of Acquired Immune Deficiency Syndromes Published Ahead of Print  a DOI: 10.1097/QAI.0000000000000328    5th Sep 2014

48. “Effects of early versus delayed initiation of antiretroviral treatment on clinical outcomes of HIV-1 infection: results from the phase 3 HPTN 052 randomised controlled trial”   B Grinsztejn, M Hosseinipour, H Ribaudo, S Swindells, J Eron, Y Chen, L Wang, San-San Ou, M Anderson, M McCauley, T Gamble, N Kumarasamy, J Hakim, J Kumwenda, J H S Pilotto, S V Godbole, S Chariyalertsak, M Gonçalves de Melo, K H Mayer, S H Eshleman, E Piwowar-Manning, J Makhema, L Mills, R Panchia, I Sanne, J Gallant, I Hoff man, T E Taha, K Nielsen-Saines, D Celentano, M Essex, D Havlir, M S Cohen, and the HPTN 052-ACTG Study Team. Lancet Infectious Diseases,Volume 14, Issue 4, Pages 281 - 290, April 2014 http://dx.doi.org/10.1016/S1473-3099(13)70692-

49. “Cost-Effectiveness of HIV Treatment as Prevention in Serodiscordant Couples” Rochelle P. Walensky, M.D., M.P.H., Eric L. Ross, B.A., Nagalingeswaran Kumarasamy, M.B., B.S., Ph.D., Robin Wood, D.Sc., Farzad Noubary, Ph.D., A. David Paltiel, Ph.D., M.B.A., Yoriko M. Nakamura, B.A., Sheela V. Godbole, M.D., Ravindre Panchia, M.B., B.Ch., Ian Sanne, M.B., B.Ch., D.T.M.&H., Milton C. Weinstein, Ph.D., Elena Losina, Ph.D., Kenneth H. Mayer, M.D., Ying Q. Chen, Ph.D., Lei Wang, Ph.D., Marybeth McCauley, M.P.H., Theresa Gamble, Ph.D., George R. Seage, III, D.Sc., M.P.H., Myron S. Cohen, M.D., and Kenneth A. Freedberg, M.D.N Engl J Med 2013;369:1715-1725October 31, 2013

50. “Self-Report of STI Symptoms, Inconsistent Condom use and Condom Nonuse are Poor Predictors of STI Prevalence among Men who have Sex with Men”. Nagarajan K, Godbole S*, Ramakrishnan L, Mainkar MK, Ramesh S, Deepika Ganju Ramesh S Paranjape (2013) Journal of AIDS & Clinical Research4:212. doi:4172/2155-6113.1000212 2013

51. ‘Risk reduction and perceived collective efficacy and community support among female sex workers in Tamil Nadu and Maharashtra, India: the importance of context.’ Mohua Guha, Angela Baschieri, Shalini Bharat,Tarun Bhatnagar, Suvarna Sanjay Sane, Sheela V Godbole, Saravanamurthy P S,Mandar Keshav Mainkar, Joseph Williams, Martine Collumbien. JECH Online First, published on July 3, 2012 as 10.1136/jech-2011-200562

52. ‘Current Status of Research on HIV Epidemic, Pathogenesis, Management and Prevention in India.’ Ramesh S. Paranjape, Madhuri R. Thakar, Manisha V. Ghate and Sheela V. Godbole. Proceedings of the National Academy of Sciences, India Section B 2012; 82(1): 167-180

53. ‘Sexually Transmitted Infections and Risk Behaviors among Transgender persons (Hijras) of Pune, India’. Sahastrabuddhe S, Gupta A, Stuart E, Godbole S, Ghate M, Sahay S, Gangakhedkar R, Risbud A, Divekar A, Bollinger R, Mehendale S. J Acquir Immune Defic Syndr 2012 Jan 1; 59(1):72-8.

54. “Prevention of HIV-1 Infection with Early Antiretroviral Therapy.” Myron S. Cohen, Ying Q. Chen, Marybeth McCauley, Theresa Gamble, Mina C. Hosseinipour, Nagalingeswaran Kumarasamy, James G. Hakim, Johnstone Kumwenda, Beatriz Grinsztejn, Jose H.S. Pilotto, Sheela V. Godbole., Sanjay Mehendale, Suwat Chariyalertsak, Breno R. Santos, Kenneth H. Mayer, Irving F. Hoffman, Susan H. Eshleman, Estelle Piwowar-Manning, Lei Wang, Joseph Makhema, Lisa A. Mills, Guy de Bruyn, Ian Sanne, Joseph Eron, Joel Gallant, Diane Havlir, Susan Swindells, Heather Ribaudo, Vanessa Elharrar, David Burns,Taha E. Taha, Karin Nielsen-Saines, David Celentano, Max Essex, and Thomas R. Fleming, for the HPTN 052 Study Team* New England Journal of Medicine 2011, 10.1056/NEJMoa1105243) July 18, 2011, at NEJM.org.

55. “Impact of Targeted Interventions on Heterosexual Transmission of HIV in India.” Rajesh Kumar, Sanjay M Mehendale, Samiran Panda, S Venkatesh, Pvm Lakshmi, Manmeet Kaur, Shankar Prinja, Tarundeep Singh, Navkiran K Virdi, Pankaj Bahuguna, Arun K Sharma, Samiksha Singh, Sheela V Godbole, Arun Risbud, Boymkesh Manna, V Thirumagal, Tarun Roy, Ruchi Sogarwal, Nilesh D Pawar. BMC Public Health 2011, 11:549

56. “Mortality in HIV infected individuals in Pune, India.” Manisha Ghate, Swapna Deshpande, Srikanth Tripathy, Sheela Godbole, Madhura Nene, Madhuri Thakar, Arun Risbud, Robert Bollinger & Sanjay Mehendale. Indian J Med Res 133, April 2011, pp 414-420

57. “Stigmatizing attitudes and low levels of knowledge but high willingness to participate in HIV Management: A community-based survey of pharmacies in Pune, India.” Amita Gupta, Suvarna S Sane, Ajay Gurbani, Robert C Bollinger, Sanjay M Mehendale, Sheela V Godbole. BMC Public Health 2010, 10:51

58. “Incidence of common opportunistic infections in HIV-infected individuals in Pune, India: analysis by stages of immunosuppression represented by CD4 counts.”Ghate M, Deshpande S, Tripathy S, Nene M, Gedam P, Godbole S, Thakar M, Risbud A, Bollinger R, Mehendale S. International Journal of Infectious Diseases.(2009)13, e1-e8

59. “HIV Infection in India : Epidemiology, molecular epidemiology and pathogenesis.” Samir Lakhashe, Madhuri Thakar, Sheela Godbole, Srikanth Tripathy and Ramesh Paranjape.Journal of Biosciences Nov 2008; 33 (4) : 515-525

60. “Biomedical research on HIV/AIDS in India.”Sheela Godbole& Sanjay Mehendale published on the web at infochangeindia.org in Februay 2008.

61. “Declining HIV incidence among patients attending Sexually transmitted Infection Clinics in Pune, India.” Sanjay M Mehendale, Nikhil Gupte, Ramesh Paranjape, Amita Gupta, Radhika Brahme, Rewa Kohli, Neelam Joglekar , Sheela V Godbole, Smita N Joshi Manisha V Ghate, Seema Sahay, B Kishore Kumar, Raman R Gangakhedkar,  Arun R Risbud, Ron Brookemeyer, Robert C Bollinger  J Acquir ImmuneDefic Syndr, Aug 15 2007 (45),5, 564-569

62. “Issues in managing and coordinating clinical research in India.”Godbole, S.,& Ghate, M. (2006).  Research Practitioner, 7(6), 219-220

63. “Same sex behaviour and high rates of HIV among men attending sexually transmitted infection clinics in Pune, India, 1993-2002.” Amita Gupta, Shruti Mehta, Sheela V Godbole, Seema Sahay, Louise Walshe, Steven J reynolds, Manisha Ghate, Raman R Gangakhedkar, Anand Divekar, Arun R Risbud, Sanjay M Mehendale, Robert C Bollinger J Acquir ImmuneDefic Syndr epub Oct 2 2006

64. “High Rates of Syphilis among STI Patients are Contributing to the Spread of HIV-1 In India.” J Reynolds, Arun R. Risbud, Mary.E. Shepherd, Anne M. Rompalo, Manisha V. Ghate, Sheela V. Godbole, Smita N Joshi, Anand D Divekar, Raman R. Gangakhedkar, Robert C. Bollinger, and Sanjay M Mehendale. Sex Transm Infections 2006;82:121-126

65. “Rate of hospitalization and inpatient care costs for HIV-1 infected persons in Pune, India.” Ghate MV, Tripathy SP, Kumar BK, Godbole SV, Chitakke A, NyanirguneP,Thakar MR, Gangakhedkar RR, Divekar AD, Risbud AR, Bollinger RC, Mehendale SM. Nat Med J India 2006; 19(1):10-14

66. “Low HIV incidence among married serodiscordant couples in Pune, India.” Mehendale S M, Ghate M V, Kumar BK, Sahay S, Gamble TR, Godbole SV, Thakar MR, Kulkarni SS, Gupta A, Gangakhedkar RR, Divekar AD, Risbud AR, Paranjape RS, Bollinger RC, J Acquir ImmuneDefic Syndr 2006; 41(3): 317-373

67. “High HIV Prevalence Among a High-Risk Subgroup of Women Attending Sexually Transmitted Infection Clinics in Pune, India.” Shruti H Mehta, Amita Gupta, Seema Sahay, Sheela VGodbole, Smita N Joshi, Steven J Reynolds, David D Celentano, Arun Risbud, Sanjay M Mehendale, Robert C Bollinger. J Acquir ImmuneDefic Syndr. 2006 Jan; 41(1):75-80

68. “Phase I safety study of Praneem polyherbal vaginal tablet use among HIV-uninfected women in Pune, India.”Joshi SN, Katti U, Godbole S, Bharucha K, B KK, Kulkarni S, Risbud A, Mehendale S.Trans R Soc Trop Med Hyg. 2005 Oct; 99(10):769-74

69. “HIV/AIDS epidemic in India: risk factors, risk behaviours and strategies for prevention and control.”Sheela Godbole& Sanjay Mehendale Indian J Med Res. 2005 Apr;121(4):356-68

70. “Fluconazole resistant non-albicans vaginal yeast in HIV seronegative women with vaginal discharge in Pune, India.” R Kairon, S Godbole, S Kulkarni, M Ghate, S Sane, A Shrotri, K Bharucha, S Mehendale, A Risbud. Int J Infect Dis. 2004 Jul; 8(4):251-2

71. “Agenda for Action: Research Priorities in HIV/AIDS in Maharashtra, India.”

A report for Avert Society Maharashtra: a Joint project of NACO, Govt. of Maharashtra and USAID. Facilitators and Editors: Dr. Seema Sahay and Dr. Sheela Godbole

72. “Efficacy and safety of three antiretroviral regimens for initial treatment of HIV-1: a randomized clinical trial in diverse multinational settings”.Campbell TB, Smeaton LM, Kumarasamy N, Flanigan T, Klingman KL, Firnhaber C, Grinsztejn B, Hosseinipour MC, Kumwenda J,Lalloo U, Riviere C, Sanchez J, Melo M, Supparatpinyo K, Tripathy S, Martinez AI, Nair A, Walawander A, Moran L, Chen Y, Snowden W,Rooney JF, Uy J, Schooley RT, De Gruttola V, Hakim JG; PEARLS study team of the ACTG. PLoS Med.2012 Aug;9(8):e1001290. Epub 2012 Aug 14. PMID: 22936892, PMCID: PMC3419182
    1. *As a Study Team Member

73. Galvanizing Evidence for HIV Management: A Consultative Meet (NARI, Pune. 27-29 Jan 2011). A report compiled by Dhayarkar S, Krishnan S, Alexander M, Ghate M, Godbole S, Gangakhedkar RR, Tripathy SP. NARI Bulletin April 2011; vol 2, Iss 2, pp 1-8.

74. Early ART (antiretroviral therapy) can prevent Sexual Transmission of HIV to uninfected partner and benefit the infected person as well": Results from the HPTN 052 Study provide a prevention option that seems like an optimal use of antiretroviral drugs for prevention! Godbole S, NARI Bulletin Oct 2011, Vol 2, Iss 4, pp 8-11.

Books and Reports and Guidelines

75. COVID-19 PANDEMIC (History, Science & Society), Chapter 5 Arrows in the Quiver: Prevention & Treatment Pages 66-85 Dr. Samiran Panda & Dr. Sheela Godbole, Published by: The Director General, Publications Division Ministry of Information and Broadcasting, Government of India, Soochna Bhawan, CGO Complex, Lodhi Road, New Delhi 03, http://www.publicationsdivision.nic.in

• Impact Evaluation of Antiretroviral Treatment Program in India. Report Commissioned by National AIDS Control Organization (NACO) Ministry of Health and Family Welfare Sep 2021

77. District-Level HIV Estimates and Prioritization in India 2019: Technical Brief, National AIDS Control Organisation & ICMR-National Institute of Medical Statistics (2021). District-Level HIV Estimates and Prioritization in India 2019: Technical Brief. New Delhi: NACO, Ministry of Health and Family Welfare, Government of India. untitled (naco.gov.in)

78. India HIV Estimates 2020: Technical Brief National AIDS Control Organisation & ICMR-National Institute of Medical Statistics (2021). District-Level HIV Estimates and Prioritization in India 2019: Technical Brief. New Delhi: NACO, Ministry of Health and Family Welfare, Government of India. untitled (naco.gov.in)

79. Reopening Schools After COVID-19 Closures, Lancet COVID Commission, Published on website April 2021

https://static1.squarespace.com/static/5ef3652ab722df11fcb2ba5d/t/60a3cff2b425ae21a5b49405/1621348340073/India+TF+Reopening+Schools+April+2021.pdf

80. Country-wide Containment Strategies for Reducing COVID-19 Cases in India, Lancet COVID Commission, Published on website April 2021

https://static1.squarespace.com/static/5ef3652ab722df11fcb2ba5d/t/60a3cf08d1c1f24480a44c19/1621348107249/India+TF+Country-wide+Containment+Strategies+April+2021.pdf

81. Checklist: Containment Strategies for Reducing COVID-19 Cases in India , Lancet COVID Commission, Published on website April 2021

https://static1.squarespace.com/static/5ef3652ab722df11fcb2ba5d/t/60a3ce9b7e2b69785d33f6e0/1621347995814/India+TF+Checklist+April+2021.pdf

• In country Data Validation, Elimination of Mother-to-Child Transmission of HIV and Syphilis. A Report Commissioned by National AIDS Control Organization (NACO) Ministry of Health and Family Welfare 2017 [Primary Author]

83. National HIV Counseling and Testing Services (HCTS) Guidelines [Writing Team]
84. India HIV Estimations 2017 Technical Report, National AIDS Control Organization & ICMR-National Institute of Medical Statistics Ministry of Health & Family Welfare Government of India
85. HIV Sentinel Surveillance 2016-17 Technical Brief, December 2017 National AIDS Control Organization [ Regional Team Leader]
86. National Integrated Biological and Behavioural Surveillance (IBBS) 2014-15, High Risk Groups in India
87. Report on INDO-US Joint Workshop on “HIV Database and Cancer Registry Match”
88. Newer Methods of HIV Prevention- Training Module in the one Year HIV Management Certificate Course offered by IGNOU [Author]

Gene Sequences submitted to and published in NCBI gene bank:

Neisseria Gonorrhoeae: gyrA, parC, mtrR sequences

gyr A: NCBI accession number: KY347918 - KY348041,14-12-16

par C: NCBI accession number: KY348042 - KY348165, 14-12-16

mtrR :NCBI accession number: KY348166 - KY348289, 14-12-16